Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
10:00am, Friday, 13'th Mar 2026
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
07:00am, Wednesday, 11'th Mar 2026
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its
3 Monster Stocks to Hold for the Next 10 Years
09:00pm, Tuesday, 10'th Mar 2026
The next big thing in artificial intelligence will very likely be located squarely between data centers and consumers. Shares of the so-called Amazon of Latin America have recently fallen out of favor
This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday
03:23pm, Tuesday, 10'th Mar 2026
Biotechnology startup CRISPR Therapeutics is issuing debt to continue developing its drug portfolio and pipeline. This new debt and/or the shareholder dilution it may lead to, however, will likely be
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
07:00am, Tuesday, 10'th Mar 2026
ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other
CRISPR Therapeutics Pivots Beyond Casgevy, Highlights CTX310 Data and New Cardiovascular Push
02:02am, Tuesday, 10'th Mar 2026
CRISPR Therapeutics (NASDAQ: CRSP) used a fireside chat at TD Cowen's 46th Annual Healthcare Conference to outline how the company is trying to broaden its identity beyond its first commercial product
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?
12:00pm, Monday, 02'nd Mar 2026
CRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow. In 2025, the company incurred a loss of more than $580 million.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
10:01am, Monday, 02'nd Mar 2026
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
09:30am, Sunday, 01'st Mar 2026
The Ark Innovation ETF is Cathie Wood's flagship fund and is heavily weighted toward innovative growth bets. The ETF recently purchased Figma, CRISPR Therapeutics, and CoreWeave.
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock
05:52am, Monday, 23'rd Feb 2026
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) General Counsel James Kasinger sold 2,112 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The stock wa
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?
12:30pm, Friday, 20'th Feb 2026
The past few years have been challenging for the biotech.
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
09:41am, Friday, 20'th Feb 2026
Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitable yet.
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street
06:10pm, Thursday, 19'th Feb 2026
Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
12:32pm, Thursday, 19'th Feb 2026
CRISPR Therapeutics AG NASDAQ: CRSP stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.
Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
11:42pm, Wednesday, 18'th Feb 2026
CRISPR Therapeutics is rated 'Buy' for its blockbuster CASGEVY launch, robust cash position, and high upside despite significant risks. CASGEVY's gene-editing therapy targets severe SCD and TDT, with
